The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...

The global flow cytometry market revenue was around US$ 4.7 billion in 2021 and is estimated to reach US$ 11.6 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.3% during the ...

Avoidable deaths are on the rise as Nigeria’s blood banks fail to deliver blood to patients requiring transfusion to survive.

The target population was composed of HIV-positive patients registered at an outpatient care ... 6-8 with similar goals and which used the same tool (CEAT-VIH) to investigate drug therapy adherence in ...

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One ...

Lenacapavir, a first-in-class capsid inhibitor, is notable for its ability to inhibit HIV at multiple stages of its lifecycle. The drug has already been green-lit in multiple countries for the ...

The global flow cytometry market revenue was around US$ 4.7 billion in 2021 and is estimated to reach US$ 11.6 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.3% during the ...

Abstract 1679, under the session ‘Drug Combination Strategies for Cancer Treatment’, showed that APG-2449, a novel focal adhesion kinase (FAK) inhibitor, enhances the anti-tumour activity of ...